Chengdu Olymvax Biopharmaceuticals Inc. (SHA:688319)

SHA:688319 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	665.75	586.1	494.29	546.68	485.29	318.91
Other Revenue	2.69	2.75	1.83	0.8	1.86	1.2
Revenue	668.43	588.86	496.12	547.48	487.15	320.11
Revenue Growth (YoY)	36.64%	18.69%	-9.38%	12.38%	52.18%	78.72%
Cost of Revenue	43.28	29.77	36.73	43.01	28.36	17.84
Gross Profit	625.15	559.09	459.39	504.48	458.79	302.27
Selling, General & Admin	417.81	389.32	336.12	352.06	296.33	223.76
Research & Development	117.72	134.23	114.73	121.99	56.36	42.73
Other Operating Expenses	7.4	3.72	3.32	3.55	3.21	2.32
Operating Expenses	563.29	537.47	455.89	489.78	364.9	274.3
Operating Income	61.86	21.62	3.51	14.7	93.89	27.97
Interest Expense	-15.49	-14.46	-7.18	-5.07	-1.23	-0.57
Interest & Investment Income	4.86	5.36	3.6	7.55	5.19	0.59
Other Non Operating Income (Expenses)	-1.04	-0.25	0.07	-0.21	-0.19	-0.43
EBT Excluding Unusual Items	50.2	12.28	-0.01	16.97	97.67	27.56
Gain (Loss) on Sale of Assets	-0.04	-0.03	-0.15	-0.15	-0.05	0
Other Unusual Items	17.55	10.06	15.77	26.83	9.57	8.57
Pretax Income	67.71	22.3	15.62	43.65	107.19	36.13
Income Tax Expense	8.04	6.58	4.18	17.07	-0.77	-
Earnings From Continuing Operations	59.67	15.72	11.44	26.58	107.96	36.13
Minority Interest in Earnings	2.23	5.04	6.11	-	-	-
Net Income	61.9	20.76	17.56	26.58	107.96	36.13
Net Income to Common	61.9	20.76	17.56	26.58	107.96	36.13
Net Income Growth	-	18.24%	-33.95%	-75.38%	198.82%	-
Shares Outstanding (Basic)	405	405	405	405	385	365
Shares Outstanding (Diluted)	405	405	405	405	385	365
Shares Change (YoY)	-0.12%	-0.01%	0.07%	5.22%	5.61%	0.89%
EPS (Basic)	0.15	0.05	0.04	0.07	0.28	0.10
EPS (Diluted)	0.15	0.05	0.04	0.07	0.28	0.10
EPS Growth	-	18.25%	-33.99%	-76.61%	182.95%	-
Free Cash Flow	-109.53	-217.05	-125.88	-225.24	-29.75	-17.76
Free Cash Flow Per Share	-0.27	-0.54	-0.31	-0.56	-0.08	-0.05
Dividend Per Share	-	-	0.038	-	-	-
Gross Margin	93.53%	94.94%	92.60%	92.14%	94.18%	94.43%
Operating Margin	9.25%	3.67%	0.71%	2.69%	19.27%	8.74%
Profit Margin	9.26%	3.52%	3.54%	4.85%	22.16%	11.29%
Free Cash Flow Margin	-16.39%	-36.86%	-25.37%	-41.14%	-6.11%	-5.55%
EBITDA	91.63	49.57	30.62	40	116.93	45.6
EBITDA Margin	13.71%	8.42%	6.17%	7.31%	24.00%	14.24%
D&A For EBITDA	29.77	27.95	27.11	25.3	23.04	17.62
EBIT	61.86	21.62	3.51	14.7	93.89	27.97
EBIT Margin	9.25%	3.67%	0.71%	2.69%	19.27%	8.74%
Effective Tax Rate	11.87%	29.52%	26.74%	39.11%	-	-
Revenue as Reported	668.43	588.86	496.12	547.48	487.15	320.11
Advertising Expenses	-	264.73	224.9	248.75	212.96	160.68

Source: S&P Global Market Intelligence. Standard template. Financial Sources.